UiPath stock was rallying Wednesday, with the automation software company set to join the S&P MidCap 400 index at the start of 2026.

News headlines UiPath (PATH) has faced recent stock declines despite a strong market backdrop, primarily due to executive stock sales and anticipated earnings. The company's automation solutions ...

・UiPath has sealed a spot in the S&P MidCap 400 index. ・The reshuffling follows a pending acquisition involving Synovus. ・In the third quarter, UiPath made a profit under GAAP rules for the first time ...

UiPath Inc. (NYSE:PATH) is one of the AI stocks under $20 to buy now. On December 9, Morgan Stanley analyst Sanjit Singh raised the firm’s price target on UiPath to $19 from $15 with an Equal Weight ...

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

UiPath (NYSE:PATH), closed Monday at $16.85, edging up 0.06%. The end-to-end automation platform provider is robotic process automation solutions with AI technology. Trading volume reached 31.3 ...

Figma is challenging Adobe with its lightweight, cloud-based AI design tools. UiPath helps companies automate tasks traditionally performed by human employees with software robots. The slower-growth ...

Enzymes help with specific functions that are vital to the operation and overall health of the human body. They help speed up chemical reactions and are essential for respiration, digestion, muscle ...